Abstrakt
Purpose of Review The history of pharmacotherapy to treat sexual desire disorders is fraught with political debate that pits clinical psychologists, sexologists, and sociologists against the sexual medicine and uro-gyn communities. This review highlights events that led to this rift and how it played out politically to influence decisions made by regulatory bodies like the US Food and Drug Administration during and after hearings to consider approving testosterone, flibanserin, and bremelanotide, for the treatment of sexual desire disorders in women.
Recent Findings The current climate for further development of pharmacotherapies is questionable due to a lack of proper marketing and a campaign of misinformation about currently approved drugs as weak, dangerous, and/or unnecessary. Pharmacotherapies work, and their promise as adjuncts to sex therapy for HSDD will give women far more choice in the kind of treatments that fit their needs.
Such treatments may well have efficacy in men and trans persons with HSDD.